{"product_id":"abcam-ab258501","title":"Abcam, ab258501, Human LRRK1 knockout HeLa cell lysate","description":"\u003cp\u003eSize: 1Kit\u003cbr\u003e\nLRRK1 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR\/Cas9, 10 bp deletion in exon8 and 1 bp deletion in exon8 and 2 bp deletion in exon8.\u003cbr\u003e\nKey facts\u003cbr\u003e\nCell type:HeLa,\u003cbr\u003e\nSpecies or organism:Human,\u003cbr\u003e\nTissue:Cervix,\u003cbr\u003e\nKnockout validation:Sanger Sequencing,\u003cbr\u003e\nMutation description:Knockout achieved by using CRISPR\/Cas9, 10 bp deletion in exon8 and 1 bp deletion in exon8 and 2 bp deletion in exon8.,\u003cbr\u003e\nDisease:Adenocarcinoma\u003c\/p\u003e\n\n\u003cp\u003eProduct details:\u003cbr\u003e\nKnockout cell lysate achieved by CRISPR\/Cas9.\u003cbr\u003e\nREACH authorisation\u003cbr\u003e\nAbcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.\u003cbr\u003e\nIt is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.\u003cbr\u003e\nLysate preparation:\u003cbr\u003e\nOur lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).\u003cbr\u003e\nThis means that the protein of interest is denatured.\u003cbr\u003e\nIf you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.\u003cbr\u003e\nUser storage instructions:\u003cbr\u003e\nLyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.\u003cbr\u003e\nThis product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our\u003cbr\u003e\nlimited use license\u003cbr\u003e\npatent pages\u003c\/p\u003e\n\n\u003cp\u003eProperties and Storage Information:\u003cbr\u003e\nGene name-LRRK1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C\u003c\/p\u003e\n\n\u003cp\u003eSupplementary Information:\u003cbr\u003e\nThis supplementary information is collated from multiple sources and compiled automatically.\u003cbr\u003e\nLRRK1 also known as leucine-rich repeat kinase 1 is an important protein with a molecular mass of approximately 273 kDa. This protein belongs to the family of serine\/threonine kinases and functions mechanically by phosphorylating other proteins a process critical for regulating various cellular processes. It is highly expressed in bone tissues with lower levels found in the liver and brain. LRRK1 also contains a GTPase domain which contributes to its kinase activity and is sometimes studied alongside its close relative LRRK2 due to structural similarities.\u003cbr\u003e\nBiological function summary\u003cbr\u003e\nLRRK1 plays a significant role in bone homeostasis and remodeling contributing to skeletal development and maintenance. LRRK1 does not form part of a larger complex but influences pathways involved in cytoskeletal dynamics and cellular motility. This protein is essential for osteoclast function where its kinase activity aids in the breakdown of bone matrix. Understanding its role in bone turnover helps researchers investigate potential therapeutic targets for bone-related conditions.\u003cbr\u003e\nPathways\u003cbr\u003e\nLRRK1 is involved in signaling pathways related to bone resorption and remodeling. It participates in the RANK\/RANKL\/OPG pathway essential for osteoclast differentiation and activation. Additionally it interacts with proteins such as c-Src and Cbl which are critical in bone matrix dissolution and cellular adhesion processes. These interactions highlight LRRK1’s pivotal role in maintaining skeletal integrity through regulated bone degradation.\u003cbr\u003e\nResearch indicates that LRRK1 can impact conditions such as osteoporosis and Paget's disease of bone. Osteoporosis involves decreased bone mass and increased fracture risk which relates to dysregulated osteoclast activity in which LRRK1 may play a part. In Paget's disease abnormal bone remodeling processes occur possibly involving dysfunctions in LRRK1 signaling. The interaction of LRRK1 with LRRK2 is also relevant in this context as both enzymes share mechanistic features that might influence bone-related pathologies.\u003c\/p\u003e","brand":"Abcam","offers":[{"title":"Default Title","offer_id":46845132406953,"sku":"ab258501","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/products\/abcam-ab258501","provider":"Iright","version":"1.0","type":"link"}